Page 137 - EJMO-9-2

Eurasian Journal of Medicine and
Oncology
Anticancer effects of phytocomposites

45. Grillari J, Grillari-Voglauer R, Jansen-Dürr P. Madame curie strategy for cancer and autoimmune diseases. J Cell Physiol.
bioscience database. In: Post-Translational Modification of 2020;235(9):5903-5924.
Cellular Proteins by Ubiquitin and Ubiquitin-Like Molecules: doi: 10.1002/jcp.29593
Role in Cellular Senescence and Ageing. Austin, TX: Landes
Bioscience; 2013. Available from: https://www.ncbi.nlm.nih. 56. Aittomäki S, Pesu M. Therapeutic targeting of the JAK/STAT
gov/books/NBK28487 pathway. Basic Clin Pharmacol Toxicol. 2013;114(1):18-23.
46. Wang Y, Shi M, Feng H, et al. Structural insights into doi: 10.1111/bcpt.12164
non-canonical ubiquitination catalyzed by side. Cell. 57. Hu Y, Hong Y, Xu Y, Liu P, Guo DH, Chen Y. Inhibition of
2018;173(5):1231-1243.e16. the JAK/STAT pathway with ruxolitinib overcomes cisplatin
doi: 10.1016/j.cell.2018.04.023 resistance in non-small-cell lung cancer NSCLC. Apoptosis.
2014;19(11):1627-1636.
47. Cherfils J, Zeghouf M. Regulation of small GTPASes by
GEFs, GAPs, and GDIs. Physiol Rev. 2013;93(1):269-309. doi: 10.1007/s10495-014-1030-z
doi: 10.1152/physrev.00003.2012 58. Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK
inhibition. Mediterr J Rheumatol. 2020;31(Suppl 1):100-104.
48. Rowinsky EK, Windle JJ, Von Hoff DD. RAS protein
farnesyltransferase: A strategic target for anticancer therapeutic doi: 10.31138/mjr.31.1.100
development. J Clin Oncol. 1999;17(11):3631-3652. 59. Gill K, Kumar R, Mohanti BK, Dey S. Assessment of p38α
doi: 10.1200/jco.1999.17.11.3631 in peripheral blood mononuclear cells (PBMC): A potential
blood protein marker of head and neck squamous cell
49. Rane N, Prendergast GC. Farnesyltransferase inhibitors:
Mechanism and applications. Expert Opin Investig Drugs. carcinoma. Clin Transl Oncol. 2013;15(11):969-973.
2001;10(12):2105-2116. doi: 10.1007/s12094-013-1031-3
doi: 10.1517/13543784.10.12.2105 60. Monnerat C, Henriksson R, Chevalier TL, et al. Phase I
study of PKC412 (N-benzoyl-staurosporine), a novel oral
50. Oh SH, Kim WY, Kim JH, et al. Identification of insulin-
like growth factor binding protein-3 as a farnesyl transferase protein kinase C inhibitor, combined with gemcitabine and
inhibitor SCH66336-induced negative regulator of cisplatin in patients with non-small-cell lung cancer. Ann
angiogenesis in head and neck squamous cell carcinoma. Oncol. 2004;15(2):316-323.
Clin Cancer Res. 2006;12(2):653-661. doi: 10.1093/annonc/mdh052
doi: 10.1158/1078-0432.ccr-05-1725 61. Lee D, Kwak HJ, Kim BH, et al. Brevilin A isolated from
Centipeda minima induces apoptosis in human gastric
51. Kelland LR, Smith V, Valenti M, et al. Preclinical antitumor
activity and pharmacodynamic studies with the farnesyl cancer cells via an extrinsic apoptotic signaling pathway.
protein transferase inhibitor R115777 in human breast Plants (Basel). 2022;11(13):1658.
cancer. Clin Cancer Res. 2001;7(11):3544-3550. doi: 10.3390/plants11131658
52. Martin LA, Head JE, Pancholi S, et al. The farnesyltransferase 62. Chen X, Du Y, Nan J, et al. Brevilin A, a novel natural
inhibitor R115777 (tipifarnib) in combination with product, inhibits janus kinase activity and blocks STAT3
tamoxifen acts synergistically to inhibit MCF-7 breast signaling in cancer cells. PLoS One. 2013;8(5):e63697.
cancer cell proliferation and cell cycle progression in vitro doi: 10.1371/journal.pone.0063697
and in vivo. Mol Cancer Ther. 2007;6(9):2458-2467.
63. Khan M, Maryam A, Saleem MZ, et al. Brevilin A induces
doi: 10.1158/1535-7163.mct-06-0452
ROS-dependent apoptosis and suppresses STAT3 activation
53. Cadelis MM, Bourguet-Kondracki ML, Dubois J, Valentin A, by direct binding in human lung cancer cells. J Cancer.
Barker D, Copp BR. Discovery and preliminary structure- 2020;11(13):3725-3735.
activity relationship studies on tecomaquinone I and tectol
as novel farnesyltransferase and plasmodial inhibitors. doi: 10.7150/jca.40983
Bioorg Med Chem. 2016;24(14):3102-3107. 64. Guan X. Cancer metastases: Challenges and opportunities.
Acta Pharm Sin B. 2015;5(5):402-418.
doi: 10.1016/j.bmc.2016.05.024
doi: 10.1016/j.apsb.2015.07.005
54. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor
AZD1480 potently blocks STAT3 signaling and oncogenesis 65. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src
in solid tumors. Cancer Cell. 2009;16(6):487-497. signaling in normal and cancer cells. Curr Opin Cell Biol.
2006;18(5):516-523.
doi: 10.1016/j.ccr.2009.10.015
doi: 10.1016/j.ceb.2006.08.011
55. Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z,
Baradaran B. Janus kinase inhibitors: A therapeutic 66. Augoff K, Hryniewicz-Jankowska A, Tabola R. Invadopodia:

Volume 9 Issue 2 (2025) 129 doi: 10.36922/ejmo.7073